The importance of genomics in advancing the diagnosis and treatment of dementia
- PMID: 35697056
- PMCID: PMC10337990
- DOI: 10.1016/S1474-4422(22)00234-4
The importance of genomics in advancing the diagnosis and treatment of dementia
Conflict of interest statement
MNS discloses ownership interest (stock or stock options) in Cortexyme, EIP Pharma, NeuroTau, Optimal Cognitive Health Company, uMETHOD, Athira Pharma, TransDermix, and Cognoptix; and receives consultancy fees from Alzheon, Biogen, Genentech (Roche Group), Acadia Pharmaceuticals, T3D Therapeutics, Eisai, Eli Lilly, KeifeRx, and NeuroTherapia. BD declares no competing interests. The work of MNS and BD is financially supported by National Institutes of Health grants (R01AG059008, P30AG072980, and R01AG073212).
Comment on
-
A human brain vascular atlas reveals diverse mediators of Alzheimer's risk.Nature. 2022 Mar;603(7903):885-892. doi: 10.1038/s41586-021-04369-3. Epub 2022 Feb 14. Nature. 2022. PMID: 35165441 Free PMC article.
-
New insights into the genetic etiology of Alzheimer's disease and related dementias.Nat Genet. 2022 Apr;54(4):412-436. doi: 10.1038/s41588-022-01024-z. Epub 2022 Apr 4. Nat Genet. 2022. PMID: 35379992 Free PMC article.
References
-
- new GWAS reference.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical